By setting out specific research areas and capability priorities, like autonomy, cyber and sensor technology, the strategy will encourage defence to be even more responsive to emerging opportunities and threats, whilst promoting more innovation and collaboration with suppliers.

The Defence Minister made the announcement while visiting Small and Medium-Sized businesses (SMEs) in Birmingham, one of the UK’s up-and-coming tech hubs, at EEF’s brand new facility in the West Midlands.

Defence Minister Harriett Baldwin said:

This new strategy puts world-beating science and technology right at the core of our Armed Forces. Investing millions into innovative ideas from dynamic British companies will help us defend the country in the face of intensifying threats and keep us ahead of the curve.

A world-leading centre for life sciences, Birmingham has over 36,800 digital jobs, with over 550 startups created from 2011 to 2015, making it a fertile ground for new ideas for UK Defence and Security.

Last year saw the department’s direct spend with smaller business increase by over 10%. Many have benefitted from the MOD’s £800 million Innovation Fund, with the department committed to spend 1.2% of its rising defence budget on science and technology.

The Defence and Security Accelerator (DASA) is one way the finances are channelled, harnessing innovative ideas to give the UK a strategic advantage in Defence and Security through themed competitions and an ‘Open Call’ for Innovation.

Since its launch, the DASA has assessed nearly 700 proposals from almost 400 organisations and has successfully awarded its defence portion of the ‘Open Call’ budget for this year.

Ideas have included computer games to help military units develop more effective tactics, a device to reduce the noise of aircraft and vehicles and a redesigned geolocation tracker.

Over 40% of submissions received were from SMEs that have not engaged with defence before, reflecting the success of the MOD efforts to make it easier for SMEs to win defence business, maximising the innovative solutions they can offer the Armed Forces.

Last month the Defence Minister announced the launch of the MOD’s new Supplier Portal, which brings together for the first time a range of useful information for new and prospective suppliers in one place.

A new Twitter channel, @defenceproc, is also being used to provide regular updates to suppliers on opportunities and events that the MOD is supporting, whilst the department also launched two simplified, plain English short-form contracts for use in lower value less complex procurements last year, reducing the existing baseline terms and conditions from 18 pages to three.

The new Science and Technology Strategy will be led by the MOD’s Chief Scientific Adviser Hugh Durrant-Whyte, who joined this year following a career at the forefront of the robotics sector in Australia.

APHA has received $100,000 in the AgResults’ Brucellosis Vaccine Prize competition, aimed at incentivising the development of a vaccine that is effective, safe and viable for use against Brucella melitensis in small ruminants across the developing world.

The award is for Phase 1 of the vaccine development and was given based on the agency’s scientific soundness, suitable research and appropriate manufacturing capabilities.

The team, led by Dr John McGiven, is now working on Phase 2, by developing a proof of concept vaccine that meets efficacy and safety requirements.

The Brucellosis Vaccine Prize competition is designed, funded and managed by AgResults, and implemented by the Global Alliance for Livestock Veterinary Medicines (GALVmed). The competition has three phases and could run for up to 10 years.

A total of $30 million is available to entrants, with 3 milestone payments at different stages, potentially adding up to the total of $26 million for one entrant. See the the competition’s website.

Brucellosis is a costly disease that affects many animals including ruminants (for example cattle, sheep, goats and buffalo) and causes abortions, infertility and decreased milk production.

It is endemic in a number of developing countries, and the toll on smallholder farmers in South Asia and Sub-Saharan Africa is particularly devastating.

Wholesale vaccination of livestock can be a cost-effective way of controlling the disease and limiting its impact on both human and animal health.

However, the existing brucellosis vaccines are not safe or efficacious enough to use effectively in developing countries. Current vaccines are unsafe for use in pregnant animals, have variable efficacy, and can harm humans.

The most protective vaccines also cause cross reactions in diagnostic tests for the disease. A new vaccine that addresses these shortcomings would deliver lasting benefits to human and animal health.

Dr John Mc Given, R&D Project Leader at the OIE Reference Laboratory for Brucellosis at APHA said:

We feel the AgResults competition elevates recognition of the significance of this insidious and debilitating disease. For many years we have been focusing on improved methods for the serodiagnosis of brucellosis and this research revealed to us a route towards a new type of vaccine against brucellosis. This competition gave us additional incentive to pull these innovative concepts together in the belief that we can make a big difference to brucellosis control.

Andrew Soldan, Head of APHA Scientific (the commercial services of APHA) said:

I think the prize competition is a fantastic idea; in the discussions I’ve already had with vaccine companies it has created a level of interest which I think is a testament to the fact that it’s already started to have an effect. It’s certainly raised the level of interest within the industry, both the research community and the vaccine companies.

To find out more about the award, listen to Andrew Soldan’s interview on the competition’s website.

Updated: The state of current progress with third country arrangements has been updated, particularly the signing of the UK-US NCA. The description of the ratification process has been updated in line with the new agreements passed in respect of Euratom.

Checklist issued for use with CLA EC-CLAIM 1 on civil escape case billing in CLA cases.